2invest AG

DB:2INV Stock Report

Market Cap: €45.0m

2invest Past Earnings Performance

Past criteria checks 1/6

2invest has been growing earnings at an average annual rate of 5.1%, while the Biotechs industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 16.9% per year.

Key information

5.07%

Earnings growth rate

6.00%

EPS growth rate

Biotechs Industry Growth-14.59%
Revenue growth rate-16.93%
Return on equity3.94%
Net Marginn/a
Last Earnings Update31 Dec 2025

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How 2invest makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2INV Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250300
30 Sep 2511500
30 Jun 2522600
31 Mar 2512400
31 Dec 2402200
30 Sep 24-11400
30 Jun 24-1500
31 Mar 24-1300
31 Dec 230200
30 Sep 231-300
30 Jun 232-800
31 Mar 233-1500
31 Dec 223-2100
30 Sep 223-2000
30 Jun 223-2000
31 Mar 222-1100
31 Dec 212-200
30 Sep 211-12-10
30 Jun 211-1200
31 Mar 2105600
31 Dec 2005500
30 Sep 20036-20
30 Jun 20036-10
31 Mar 201-440
31 Dec 190-3300
30 Sep 19-7-4-10
30 Jun 19-4-300
31 Mar 19-1-330
31 Dec 181-340
30 Sep 1812-2101
30 Jun 1810-3101
31 Mar 189-391
31 Dec 178-481
30 Sep 176-581
30 Jun 174-561
31 Mar 173-551
31 Dec 162-431
30 Sep 161-331
30 Jun 161-431
31 Mar 161-431
31 Dec 151-431
30 Sep 150-421
30 Jun 150-421

Quality Earnings: 2INV has a large one-off gain of €2.0M impacting its last 12 months of financial results to 31st December, 2025.

Growing Profit Margin: Insufficient data to determine if 2INV's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2INV's earnings have grown by 5.1% per year over the past 5 years.

Accelerating Growth: 2INV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2INV had negative earnings growth (-84.7%) over the past year, making it difficult to compare to the Biotechs industry average (4.2%).


Return on Equity

High ROE: 2INV's Return on Equity (3.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 01:39
End of Day Share Price 2026/06/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

2invest AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew Murray DarleyCavendish
Mark BrewerCavendish
Christian OrqueraFirst Berlin Equity Research GmbH